{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:45:15Z","timestamp":1791945915366,"version":"4.3.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pharmacy Research Project of Hengrui Hospital of Jiangsu Pharmaceutical Association","award":["H202029"],"award-info":[{"award-number":["H202029"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Spinal muscular atrophy (SMA) is a rare neurodegenerative disease that significantly affects multiple systems in children. Nusinersen, the first approved treatment for SMA, enhances SMN protein production by targeting the RNA splicing site of the SMN2 gene, thus improving motor function. However, the high cost of nusinersen treatment raises concerns about its economic feasibility.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study retrospectively analyzed clinical data of 42 pediatric SMA patients treated with nusinersen from January 2022 to October 2024 at our hospital. We assessed the efficacy, safety, and economic impact of nusinersen in different SMA types. Motor function was evaluated using the CHOP-INTEND, HINE-2, HFMSE, and RULM scales. Safety was assessed based on adverse reactions and events, and economic evaluation considered total treatment costs and average cost per injection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Nusinersen significantly improved motor function in SMA patients, especially in type I patients, who showed notable increases in CHOP-INTEND and HINE-2 scores. The RULM score had the highest increase among type II patients, while improvements were relatively lower in type III patients. Regarding safety, the incidence of adverse events was 40.48%, with fever being the most common adverse reaction, occurring in 36.36% of cases. Economic analysis indicated that the total treatment cost was highest for type III patients, though the cost differences among types were not statistically significant (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Nusinersen demonstrated significant clinical efficacy and favorable safety in pediatric SMA patients, with improved economic feasibility after insurance coverage. Our findings support early SMA screening and presymptomatic nusinersen administration to maximize therapeutic benefits. Further multicenter, large-sample, long-term follow-up studies are warranted to validate and expand upon these findings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03603-9","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T13:59:41Z","timestamp":1740578381000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-world analysis of the efficacy and safety of nusinersen in pediatric patients with spinal muscular atrophy"],"prefix":"10.1186","volume":"20","author":[{"given":"Wenjing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"issue":"5","key":"3603_CR1","first-page":"693","volume":"35","author":"C Wurster","year":"2022","unstructured":"Wurster C, Petri S. Progress in spinal muscular atrophy research. Curr Opin Neurol. 2022;35(5):693\u20138.","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"3603_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: Part1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103\u201315.","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"3603_CR3","first-page":"263","volume":"37","author":"Writing Group for Practice Guidelines for Diagnosis and Treatment of Genetic Diseases, Medical Genetics Branch of Chinese Medical Association","year":"2020","unstructured":"Writing Group for Practice Guidelines for Diagnosis and Treatment of Genetic Diseases, Medical Genetics Branch of Chinese Medical Association. Clinical practice guidelines for spinal muscular atrophy. Chin J Med Genet. 2020;37(3):263\u20138.","journal-title":"Chin J Med Genet"},{"issue":"1","key":"3603_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ejhg.2011.134","volume":"20","author":"EA Sugarman","year":"2012","unstructured":"Sugarman EA, Nagan N, Zhe H, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >\u200972440 specimens. Eur J Hum Genetics: EJHG. 2012;20(1):27\u201332.","journal-title":"Eur J Hum Genetics: EJHG"},{"issue":"3","key":"3603_CR5","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.pcl.2015.03.010","volume":"62","author":"BT Darras","year":"2015","unstructured":"Darras BT. Spinal muscular atrophy. Pediatr Clin N Am. 2015;62(3):743\u201366.","journal-title":"Pediatr Clin N Am"},{"issue":"22","key":"3603_CR6","first-page":"1785","volume":"56","author":"X Junmei Shang","year":"2021","unstructured":"Junmei Shang X, Liu L, Chen, et al. Application progress of multi-criteria decision analysis in assessment of orphan drugs. Chin Pharm J. 2021;56(22):1785\u201390.","journal-title":"Chin Pharm J"},{"issue":"2","key":"3603_CR7","first-page":"231","volume":"2","author":"Y Dai","year":"2023","unstructured":"Dai Y. Liying Cui. Clinical practice guideline for adolescent & adult patients with spinal muscular atrophy. J Rare Dis. 2023;2(2):231\u201355.","journal-title":"J Rare Dis"},{"key":"3603_CR8","volume-title":"Report of rare diseases in China (2018) [M]","author":"J Lin Wang","year":"2018","unstructured":"Lin Wang J, Ding. Report of rare diseases in China (2018) [M]. Beijing: China Medical Science; 2018."},{"issue":"9","key":"3603_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/gt.2017.52","volume":"24","author":"K Talbot","year":"2017","unstructured":"Talbot K, Tizzano EF. The clinical landscape for SMA in a new therapeutic era. Gene Ther. 2017;24(9):529\u201333.","journal-title":"Gene Ther"},{"issue":"4","key":"3603_CR10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1177\/0883073811420152","volume":"27","author":"X Ge","year":"2012","unstructured":"Ge X, Bai J, Lu Y, et al. The natural history of infant spinal muscular atrophy in China: a study of 237 patients. J Child Neurol. 2012;27(4):471\u20137.","journal-title":"J Child Neurol"},{"key":"3603_CR11","first-page":"1348","volume":"26","author":"JR Nance","year":"2020","unstructured":"Nance JR. Spinal muscular atrophy. Continuum (Minneap Minn). 2020;26:1348\u201368.","journal-title":"Continuum (Minneap Minn)"},{"key":"3603_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nrneurol.2015.77","volume":"11","author":"I Faravelli","year":"2015","unstructured":"Faravelli I, Nizzardo M, Comi GP, et al. Spinal muscular atrophy-recent therapeutic advances for an old challenge. Nat Rev Neurol. 2015;11:351\u20139.","journal-title":"Nat Rev Neurol"},{"issue":"3\u20134","key":"3603_CR13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.18071\/isz.71.0090","volume":"71","author":"G Sinko","year":"2018","unstructured":"Sinko G, Kiss Z, Kalman B. Nusinersen in the treatment of spinal muscular atrophy. Ideggyogy Sz. 2018;71(3\u20134):90\u20134.","journal-title":"Ideggyogy Sz"},{"issue":"3","key":"3603_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28(3):197\u2013207.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"3603_CR15","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","volume":"16","author":"G Coratti","year":"2021","unstructured":"Coratti G, Cutrona C, Pera MC, et al. Motor function in type 2 and 3 SMA patients treated with nusinersen: a critical review and meta-analysis. Orphanet J Rare Dis. 2021;16(1):430.","journal-title":"Orphanet J Rare Dis"},{"issue":"9\/10","key":"3603_CR16","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","volume":"17","author":"JM O\u2019Hagen","year":"2007","unstructured":"O\u2019Hagen JM, Glanzman AM, McDermott MP, et al. An expanded version of the hammersmith functional motor scale for SMA II and III patients. Neuromuscul Disord. 2007;17(9\/10):693\u20137.","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"3603_CR17","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1177\/0883073811420294","volume":"26","author":"AM Glanzman","year":"2011","unstructured":"Glanzman AM, O\u2019Hagen JM, McDermott MP, et al. Validation of the expanded hammersmith functional motor scale in spinal muscular atrophy type II and III. J Child Neurol. 2011;26(12):1499\u2013507.","journal-title":"J Child Neurol"},{"issue":"18","key":"3603_CR18","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332.","journal-title":"N Engl J Med"},{"issue":"Supplement 2","key":"3603_CR19","first-page":"S210","volume":"27","author":"E Mercuri","year":"2017","unstructured":"Mercuri E, Finkel R, Kirschner J, et al. Efficacy and safety of Nusinersen in children with later onset spinal muscular atrophy (SMA): end of study results from the phase 3 CHERISH study. Neuromuscul Disord. 2017;27(Supplement 2):S210.","journal-title":"Neuromuscul Disord"},{"issue":"21","key":"3603_CR20","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","volume":"92","author":"BT Darras","year":"2019","unstructured":"Darras BT, Chiriboga CA, Iannaccone ST, et al. Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies. Neurology. 2019;92(21):e2492\u2013506.","journal-title":"Neurology"},{"issue":"1","key":"3603_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13023-020-01638-8","volume":"16","author":"M Yao","year":"2021","unstructured":"Yao M, Ma Y, Qian RY, et al. Quality of life of children with spinal muscular atrophy and their caregivers from the perspective of caregivers: a Chinese cross-sectional study. Orphanet J Rare Dis. 2021;16(1):7.","journal-title":"Orphanet J Rare Dis"},{"issue":"17","key":"3603_CR22","first-page":"1413","volume":"57","author":"TT Xu","year":"2022","unstructured":"Xu TT, Liu X, Zhang CL, et al. Research progress on the effectiveness and safety of nusinersen in the treatment of spinal muscular atrophy. Chin Pharm J. 2022;57(17):1413\u20138.","journal-title":"Chin Pharm J"},{"key":"3603_CR23","unstructured":"Rare disease branch of Beijing Medical Association. Expert consensus on multidisciplinary management of spinal muscular atrophy. Chin Med J. 2019(19):1460\u20137."},{"issue":"3","key":"3603_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00431-002-1122-6","volume":"162","author":"E Janssens","year":"2003","unstructured":"Janssens E, Aerssens P, Alli TP, et al. Post-dural puncture headaches in children. A literature review. Eur J Pediatr. 2003;162(3):117\u201321.","journal-title":"Eur J Pediatr"},{"issue":"12","key":"3603_CR25","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1177\/0333102412453951","volume":"32","author":"JA Amorim","year":"2012","unstructured":"Amorim JA, Gomes de Barros MV, Valen AMM. Post-dural(post-lumbar) puncture headaches: risk factors and clinical features. Cephalagia. 2012;32(12):916\u201323.","journal-title":"Cephalagia"},{"issue":"4","key":"3603_CR26","first-page":"286","volume":"18","author":"K Ma","year":"2023","unstructured":"Ma K, Guo XH, Yu CM, et al. Nusinersen treatment in 68 children with 5q spinal muscular atrophy: a case series report. Chin J Evid Based Pediatr. 2023;18(4):286\u201390.","journal-title":"Chin J Evid Based Pediatr"},{"issue":"7","key":"3603_CR27","first-page":"688","volume":"60","author":"Y Shanshan Mao","year":"2022","unstructured":"Shanshan Mao Y, Feng L, Xu, et al. Clinical follow-up analysis of nusinersen in the disease-modifying treatment of pediatric spinal muscular atrophy. Chin J Pediatr. 2022;60(7):688\u201393.","journal-title":"Chin J Pediatr"},{"issue":"1","key":"3603_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/1060028018789956","volume":"53","author":"KC Melanie","year":"2019","unstructured":"Melanie KC, Debra LS, Cheri KW, et al. Nusinersen: a treatment for spinal muscular atrophy. Ann Pharmacother. 2019;53(1):61\u20139.","journal-title":"Ann Pharmacother"},{"issue":"16","key":"3603_CR29","first-page":"1665","volume":"41","author":"ZR Fu","year":"2021","unstructured":"Fu ZR, Zhu Y, Wang XL, et al. Real-world study of adverse reactions of nusinersen based upon openFDA. Chin J Hosp Pharm. 2021;41(16):1665\u20139.","journal-title":"Chin J Hosp Pharm"},{"issue":"9","key":"3603_CR30","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40263-019-00656-w","volume":"33","author":"BT Darras","year":"2019","unstructured":"Darras BT, Farrar MA, Mercuri E, et al. An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with nusinersen in seven clinical trials. CNS Drugs. 2019;33(9):919\u201332.","journal-title":"CNS Drugs"},{"issue":"15","key":"3603_CR31","doi-asserted-by":"publisher","first-page":"7896","DOI":"10.3390\/ijms22157896","volume":"22","author":"MER Butchbach","year":"2021","unstructured":"Butchbach MER. Genomic variability in the survival motor neuron genes (SMN1 and SMN2): implication for spinal muscular atrophy phenotype and therapeutics development. Int Mol Sci. 2021;22(15):7896.","journal-title":"Int Mol Sci"},{"issue":"6","key":"3603_CR32","first-page":"721","volume":"32","author":"Y Zheng Chen, Nevo","year":"2019","unstructured":"Zheng Chen, Nevo Y, Moss T. Nusinersen in the treatment of spinal muscular atrophy. Chin J Clin Res. 2019;32(6):721\u20135.","journal-title":"Chin J Clin Res"},{"issue":"9","key":"3603_CR33","first-page":"883","volume":"60","author":"The Subspecialty Group of Rehabilitation, the Society of Pediatrics, Chinese Medical Association","year":"2022","unstructured":"The Subspecialty Group of Rehabilitation, the Society of Pediatrics, Chinese Medical Association. Physical Therapy Committee of Chinese Association of Rehabilitation Medicine. Expert consensus on rehabilitation management of the spinal muscular atrophy. Chin J Pediatr. 2022;60(9):883\u20137.","journal-title":"Chin J Pediatr"},{"key":"3603_CR34","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3233\/JND-200617","volume":"8","author":"J Slayter","year":"2021","unstructured":"Slayter J, Hodgkinson V, Lounsberry J, et al. A Canadian adult spinal muscular atrophy outcome measures toolkit: results of a national consensus using a modified delphi method. J Neuromuscul Dis. 2021;8:579\u201388.","journal-title":"J Neuromuscul Dis"},{"issue":"4","key":"3603_CR35","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/PEP.0b013e3182351f04","volume":"23","author":"AM Glanzman","year":"2011","unstructured":"Glanzman AM, McDermott MP, Montes J, et al. Validation of the children\u2019s hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND). Pediatr Phys Ther. 2011;23(4):322\u20136.","journal-title":"Pediatr Phys Ther"},{"issue":"4","key":"3603_CR36","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/mus.26419","volume":"59","author":"MC Pera","year":"2019","unstructured":"Pera MC, Coratti G, Mazzone ES, et al. Revised upper limb module for spinal muscular atrophy: 12 month changes. Muscle Nerve. 2019;59(4):426\u201330.","journal-title":"Muscle Nerve"},{"issue":"9","key":"3603_CR37","doi-asserted-by":"publisher","first-page":"e0238786","DOI":"10.1371\/journal.pone.0238786","volume":"15","author":"D Trundell","year":"2020","unstructured":"Trundell D, Le Scouiller S, Le Goff L, et al. Assessment of the validity and reliability of the 32-item motor function measure in individuals with type 2 or non-ambulant type 3 spinal muscular atrophy. PLoS ONE. 2020;15(9):e0238786.","journal-title":"PLoS ONE"},{"issue":"1","key":"3603_CR38","first-page":"1","volume":"18","author":"Working group for clinical practice guidelines on spinal muscular atrophy","year":"2023","unstructured":"Working group for clinical practice guidelines on spinal muscular atrophy. Clinical practice guidelines for spinal muscular atrophy. Chin J Evidence-Based Pediatr. 2023;18(1):1\u201312.","journal-title":"Chin J Evidence-Based Pediatr"},{"issue":"14","key":"3603_CR39","first-page":"e1988","volume":"95","author":"CA Wijinaarde","year":"2020","unstructured":"Wijinaarde CA, Stam M, Otto LAM, et al. Muscle strength and motor function in adolescents and adults with spinal muscular atrophy. Neurology. 2020;95(14):e1988\u201398.","journal-title":"Neurology"},{"key":"3603_CR40","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/JND-190416","volume":"6","author":"MC Walter","year":"2019","unstructured":"Walter MC, Wenninger S, Thiele S, et al. Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3-A prospective observational study. J Neuromuscul Dis. 2019;6:453\u201365.","journal-title":"J Neuromuscul Dis"},{"issue":"9","key":"3603_CR41","first-page":"A02200100","volume":"67","author":"SS Albrechtsen","year":"2020","unstructured":"Albrechtsen SS, Born AP, Boesen MS. Nusinersen treatment of spinal muscular atrophy\u2013 a systematic review. Dan Med J. 2020;67(9):A02200100.","journal-title":"Dan Med J"},{"issue":"11","key":"3603_CR42","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1136\/jnnp-2020-324532","volume":"92","author":"SH Chan","year":"2021","unstructured":"Chan SH, Chae J, Chien Y, et al. Nusinersen in spinal muscular atrophy type 1 from neonates to young adult: 1-year data from three Asia-Pacific regions. J Neurol Neurosurg Psychiatry. 2021;92(11):1244.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"3603_CR43","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1089\/nat.2016.0650","volume":"27","author":"ST Crooke","year":"2017","unstructured":"Crooke ST, Baker BF, Witztum JL, et al. The effe3cts of 2\u2019-o-methoxyethyl containing antisense oligonucleotides on platelets in human clinical trial. Nucleic Acid Ther. 2017;27(3):121\u20139.","journal-title":"Nucleic Acid Ther"},{"issue":"20","key":"3603_CR44","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1212\/WNL.0000000000006502","volume":"91","author":"D Michelson","year":"2018","unstructured":"Michelson D, Ciafaloni E, Ashwal S, et al. Evidence in focus: Nusinersen use in spinal muscular atrophy: report of the Guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;91(20):923\u201333.","journal-title":"Neurology"},{"issue":"10","key":"3603_CR45","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1097\/BPO.0000000000001247","volume":"38","author":"KA Strauss","year":"2018","unstructured":"Strauss KA, Carson VJ, Brigatti KW, et al. Preliminary safety and tolerability of a novel subcutaneous intrathecal catheter system for repeated outpatient dosing of nusinersen to children and adults with spinal atrophy. J Pediatr Orthop. 2018;38(10):e610\u20137.","journal-title":"J Pediatr Orthop"},{"key":"3603_CR46","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(rx))in children with spinal muscular atrophy. Neurology. 2016;86:890\u20137.","journal-title":"Neurology"},{"issue":"10063","key":"3603_CR47","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017\u201326.","journal-title":"Lancet"},{"issue":"6","key":"3603_CR48","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamainternmed.2018.0869","volume":"178","author":"MS Gerrity","year":"2018","unstructured":"Gerrity MS, Prasad V, Obley AJ. Concerns about the approval of nusinersen sodium by the US Food and Drug Administration. JAMA Intern Med. 2018;178(6):743\u20134.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"3603_CR49","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40273-019-00769-6","volume":"7","author":"S Zuluaga-Sanchez","year":"2019","unstructured":"Zuluaga-Sanchez S, Teynor M, Knight C, et al. Cost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden. PharmacoEconomics. 2019;7(6):845\u201365.","journal-title":"PharmacoEconomics"},{"key":"3603_CR50","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jpeds.2020.07.033","volume":"227","author":"A Jalali","year":"2020","unstructured":"Jalali A, Rothwell E, Botkin JR, et al. Cost-effectiveness of nusinersen and universal newborn screening for spinal muscular atrophy. J Pediatr. 2020;227:274\u201380.","journal-title":"J Pediatr"},{"issue":"1","key":"3603_CR51","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13023-021-01695-7","volume":"16","author":"T Dangouloff","year":"2021","unstructured":"Dangouloff T, Botty C, Beaudart C, et al. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis. 2021;16(1):47.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03603-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03603-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03603-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T01:40:57Z","timestamp":1740620457000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03603-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3603"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03603-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Children\u2019s Hospital of Nanjing Medical University, and informed consent from patients was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}